CVSI-007

**CVSI-007** is an investigational fixed-dose chewing-gum formulation developed by **CV Sciences** for cessation of smokeless tobacco use and treatment of smokeless tobacco addiction. It combines synthetic cannabidiol and nicotine delivered as nicotine-polacrilex. Nicotine replacement is intended to reduce nicotine withdrawal and craving through activation of neuronal nicotinic acetylcholine receptors, while cannabidiol is included as an adjunct intended to support treatment of nicotine addiction. CV Sciences held a pre-IND meeting with the FDA in June 2017 and described a planned U.S. 505(b)(2) development pathway referencing nicotine-polacrilex gum; subsequent company communications reported patent grants and continued efforts to advance the program. ([ir.cvsciences.com](https://ir.cvsciences.com/press-releases/detail/24/cv-sciences-inc-announces-commencement-of-ind-preparation))

Other names

CBD + nicotinecannabidiol + nicotinecannabidiol + nicotine-polacrilexsynthetic cannabidiol + nicotine-polacrilex